In 2020, it became the only diabetic drug to be approved for reducing or preventing the risk of major cardiovascular events (MACE) in patients with type 2 diabetes
Ro launches the GLP-1 Supply Tracker News provided by Ro May 29, 2024, 09:01 ET Tool gives patients real-time insights on GLP-1 drug shortages and automated, localized supply alerts NEW YORK, May 29, 2024 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today launched the GLP-1 Supply Tracker, an interactive tool to give patients real-time insights on GLP-1 drug shortages and automated, localized supply alerts
These drugs are FDA-approved for type 2 diabetes and obesity, but growing evidence supports their use for rheumatoid arthritis, psoriatic arthritis, lupus, osteoarthritis, and metabolic/autoimmune diseases. Who should not take GLP-1 medications
Adaptive thermogenesis in humans
Using insulin syringes with half-unit markings improves accuracy for small volumes
Since Retatrutide is likely to compete with weight loss injections such as Mounjaro and Wegovy, the cost should be similar to those treatments
